Chris Simpson is a corporate and transactional attorney that advises clients across the spectrum – from growth-oriented companies to venture and growth equity funds – on significant company equity fundraises, mergers, acquisitions, strategic collaborations and similar transactions as well as day to day operative and commercial matters.  

Venture Capital and Growth Equity

A significant portion of Chris’ practice is dedicated to working with entrepreneurs and early growth stage companies, and Chris has helped countless companies navigate their way through Series Seed, A and B fundraises to exit transactions.

Chris also counsels venture capital and growth equity funds in connection with their debt and equity financing investments in private companies.

General Outside Counsel

Chris works as general outside counsel to private companies, helping them with day-to-day legal guidance and larger strategic transactions.

AgTech, Food and Beverage, Tech and Life Sciences

Chris expertly advises agtech, food and beverage, tech and life science companies from start-up stage to public companies on various corporate matters including negotiating investments, mergers and acquisitions, strategic collaborations and joint ventures and public offerings.

Cross-Border Experience

A large portion of Chris’ experience has involved cross-border transactions in the life sciences and agtech space, including cross-border acquisitions, financings, joint ventures and collaborations.

Before Polsinelli, Chris practiced at Choate, Hall & Stewart, LLP in Boston Massachusetts.

  • Representation of a private agtech company in a $25MM equity fundraise.
  • Representation of a private agtech company in sale to international publicly traded company.
  • Representation of a cloud security company in a $10MM fundraise. 
  • Representation of numerous other agtech, food and beverage, life science and technology companies in seed, Series A and successive rounds of venture capital and growth equity financings. 
  • Representation of publicly-traded pharmaceutical company in $1 billion+ acquisition of drug-development company. 
  • Representation of multi-national contract drug manufacturer in acquisition of laboratory spun off from a major US university. 
  • Representation of a pre-commercial drug development company in a number of cross-border research and licensing collaborations with non-US companies and universities. 
  • Representation of a Swiss medical device company in its sale to a US publicly-traded company. 
  • Representation of numerous life science and technology companies in seed, Series A and successive rounds of venture capital and growth equity financings. 
  • Representation of leading venture capital firm in financing of life science companies.
  • Representation of leading growth equity firm in financing of healthcare IT companies. 
  • Representation of private equity-backed home health and hospice company in multiple roll-up acquisitions.
  • Representation of biotechnology company in a variety of commercial matters, including manufacturing agreements, license agreements and sponsored research agreements.